

DECISION LETTER FOR VACCINE SUPPORT

This Decision Letter sets out the Programme Terms

1. Country: Republic of Kenya																
2. Vaccines Grant Number: 1314-KEN-19b-X Cash Support Grant Number: 1314-KEN-24a-Y																
3. Decision Letter no: 1																
4. Date of the Partnership Framework Agreement: Not applicable																
5. Programme Title: HPV Demonstration Programme																
6. Vaccine type: HPV																
7. Preferred product presentation and formulation of vaccine: HPV quadrivalent, 1 dose(s) per vial, LIQUID																
8. Programme Duration¹: 2013 – 2014																
9. Programme Budget (indicative): <table border="1" data-bbox="293 929 1311 1137"><thead><tr><th></th><th>2013</th><th>2014</th><th>Total²</th></tr></thead><tbody><tr><td>HPV vaccines (US\$)</td><td>\$153,500</td><td>\$139,500</td><td>\$293,000</td></tr><tr><td>Cash (\$)</td><td>\$145,000</td><td>\$25,000</td><td>\$170,000</td></tr><tr><td>Total Programme Budget (US\$)</td><td>\$298,500</td><td>\$164,500</td><td>\$463,000</td></tr></tbody></table>		2013	2014	Total ²	HPV vaccines (US\$)	\$153,500	\$139,500	\$293,000	Cash (\$)	\$145,000	\$25,000	\$170,000	Total Programme Budget (US\$)	\$298,500	\$164,500	\$463,000
	2013	2014	Total ²													
HPV vaccines (US\$)	\$153,500	\$139,500	\$293,000													
Cash (\$)	\$145,000	\$25,000	\$170,000													
Total Programme Budget (US\$)	\$298,500	\$164,500	\$463,000													
10. Vaccine Introduction Grant: Not applicable																
11. Indicative Annual Amounts:³ <i>Vaccines</i> <table border="1" data-bbox="304 1355 1299 1597"><thead><tr><th>Type of supplies to be purchased with GAVI funds in each year</th><th>2013</th><th>2014</th></tr></thead><tbody><tr><td>Number of HPV vaccines doses</td><td>29,872</td><td>27,156</td></tr><tr><td>Number of AD syringes</td><td>31,722</td><td>28,708</td></tr><tr><td>Annual Amounts (US\$)</td><td>\$153,500</td><td>\$139,500</td></tr></tbody></table> <i>Cash support:</i> <table border="1" data-bbox="379 1736 1224 1870"><tbody><tr><td>Cash Support by year</td><td>2013</td></tr><tr><td>Annual Amounts (US\$)</td><td>\$145,000</td></tr></tbody></table>	Type of supplies to be purchased with GAVI funds in each year	2013	2014	Number of HPV vaccines doses	29,872	27,156	Number of AD syringes	31,722	28,708	Annual Amounts (US\$)	\$153,500	\$139,500	Cash Support by year	2013	Annual Amounts (US\$)	\$145,000
Type of supplies to be purchased with GAVI funds in each year	2013	2014														
Number of HPV vaccines doses	29,872	27,156														
Number of AD syringes	31,722	28,708														
Annual Amounts (US\$)	\$153,500	\$139,500														
Cash Support by year	2013															
Annual Amounts (US\$)	\$145,000															

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

DECISION LETTER FOR VACCINE SUPPORT

12. Procurement agency: UNICEF								
13. Self-procurement: Not applicable								
14. Co-financing obligations: Not applicable								
15. Operational support for campaigns: Not applicable								
16. Documents to be delivered for future disbursements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts. Further details can be found in the HPV Guidelines for Applications 2012.								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%; text-align: center;">Reports, documents and other deliverables</th> <th style="width: 40%; text-align: center;">Due dates</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;"> 1. A report of the evaluation of the HPV demonstration programme. 2. A copy of the approval by the local ethics committee, if a country determined that review and approval was required. 3. A report of the feasibility assessment of adolescent health interventions, with conclusions about what interventions are or are not feasible. 4. If an adolescent health intervention is identified for joint delivery with HPV vaccine, a description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved. 5. A summary of the activities completed and progress towards development of a national cervical cancer prevention and control strategy. </td> <td style="padding: 5px; vertical-align: top;">End of first year (the first year starts when the first dose of vaccine is administered)</td> </tr> <tr> <td style="padding: 5px;">1. Financial reports for the GAVI HPV demonstration programme covering the year ended, in form and substance satisfactory to GAVI.</td> <td style="padding: 5px; vertical-align: top;">Within 3 months of the end of each Country's fiscal year.</td> </tr> <tr> <td style="padding: 5px;"> 1. A summary report of year two delivery of HPV vaccinations, if not jointly delivered with adolescent health interventions. 2. If HPV was delivered jointly with adolescent health interventions, based on the year one feasibility assessment, an evaluation report of that delivery is required. 3. A copy of the developed or revised national cervical cancer prevention and control strategy. </td> <td style="padding: 5px; vertical-align: top;">End of second year (the first year starts when the first dose of vaccine is administered and continues for twelve calendar months)</td> </tr> </tbody> </table>	Reports, documents and other deliverables	Due dates	1. A report of the evaluation of the HPV demonstration programme. 2. A copy of the approval by the local ethics committee, if a country determined that review and approval was required. 3. A report of the feasibility assessment of adolescent health interventions, with conclusions about what interventions are or are not feasible. 4. If an adolescent health intervention is identified for joint delivery with HPV vaccine, a description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved. 5. A summary of the activities completed and progress towards development of a national cervical cancer prevention and control strategy.	End of first year (the first year starts when the first dose of vaccine is administered)	1. Financial reports for the GAVI HPV demonstration programme covering the year ended, in form and substance satisfactory to GAVI.	Within 3 months of the end of each Country's fiscal year.	1. A summary report of year two delivery of HPV vaccinations, if not jointly delivered with adolescent health interventions. 2. If HPV was delivered jointly with adolescent health interventions, based on the year one feasibility assessment, an evaluation report of that delivery is required. 3. A copy of the developed or revised national cervical cancer prevention and control strategy.	End of second year (the first year starts when the first dose of vaccine is administered and continues for twelve calendar months)
Reports, documents and other deliverables	Due dates							
1. A report of the evaluation of the HPV demonstration programme. 2. A copy of the approval by the local ethics committee, if a country determined that review and approval was required. 3. A report of the feasibility assessment of adolescent health interventions, with conclusions about what interventions are or are not feasible. 4. If an adolescent health intervention is identified for joint delivery with HPV vaccine, a description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved. 5. A summary of the activities completed and progress towards development of a national cervical cancer prevention and control strategy.	End of first year (the first year starts when the first dose of vaccine is administered)							
1. Financial reports for the GAVI HPV demonstration programme covering the year ended, in form and substance satisfactory to GAVI.	Within 3 months of the end of each Country's fiscal year.							
1. A summary report of year two delivery of HPV vaccinations, if not jointly delivered with adolescent health interventions. 2. If HPV was delivered jointly with adolescent health interventions, based on the year one feasibility assessment, an evaluation report of that delivery is required. 3. A copy of the developed or revised national cervical cancer prevention and control strategy.	End of second year (the first year starts when the first dose of vaccine is administered and continues for twelve calendar months)							
17. Clarifications: Programmatic clarifications satisfactorily submitted								
18. Other conditions: GAVI will disburse USD 145,000 in the first year. In the second year, GAVI will disburse USD 25,000 if the Country satisfies the following conditions: (i) the report of the feasibility assessment of adolescent health interventions has a conclusion that the interventions are feasible; and (ii) the Country has submitted description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved.								

On behalf of the GAVI Alliance

Signed by:

Date: 21st May 2013



Hind Khatib-Othman
Managing Director, Country Programmes